Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Nasdaq

If You Invested $1000 In This Stock 15 Years Ago, You Would Have $19,000 Today

Lululemon Athletica (NASDAQ:LULU) has outperformed the market over the past 15 years by 15.34% on an annualized basis producing an average annual return of 21.64%. Currently, Lululemon Athletica has a market capitalization of $36.12 billion.

Benzinga

Here's How Much You Would Have Made Owning Lam Research Stock In The Last 5 Years

Lam Research (NASDAQ:LRCX) has outperformed the market over the past 5 years by 15.15% on an annualized basis producing an average annual return of 24.54%. Currently, Lam Research has a market capitalization of $59.24 billion.

Benzinga

Expert Ratings for Plug Power

Plug Power (NASDAQ:PLUG) has observed the following analyst ratings within the last quarter:

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

What 6 Analyst Ratings Have To Say About Grocery Outlet Holding

Within the last quarter, Grocery Outlet Holding (NASDAQ:GO) has observed the following analyst ratings:

Benzinga

Expert Ratings for ON Semiconductor

Within the last quarter, ON Semiconductor (NASDAQ:ON) has observed the following analyst ratings:

Benzinga

Analyst Ratings for Broadcom

Broadcom (NASDAQ:AVGO) has observed the following analyst ratings within the last quarter:

Benzinga

Where Affirm Holdings Stands With Analysts

Analysts have provided the following ratings for Affirm Holdings (NASDAQ:AFRM) within the last quarter:

Benzinga

Read news from The Economist, FT, and more,
with one subscription

What 14 Analyst Ratings Have To Say About Ambarella

Analysts have provided the following ratings for Ambarella (NASDAQ:AMBA) within the last quarter:

Benzinga

What 4 Analyst Ratings Have To Say About Hamilton Lane

Hamilton Lane (NASDAQ:HLNE) has observed the following analyst ratings within the last quarter:

Benzinga

What Are Whales Doing With CrowdStrike Holdings

A whale with a lot of money to spend has taken a noticeably bullish stance on CrowdStrike Holdings. Looking at options history for CrowdStrike Holdings (NASDAQ:CRWD) we detected 14 strange trades.

Benzinga

Where Teradyne Stands With Analysts

Analysts have provided the following ratings for Teradyne (NASDAQ:TER) within the last quarter:

Benzinga

What 14 Analyst Ratings Have To Say About Advanced Micro Devices

Within the last quarter, Advanced Micro Devices (NASDAQ:AMD) has observed the following analyst ratings:

Benzinga

Better Tips For Uber Drivers, Consider Getting A Tesla

Ride-share drivers are turning to renting or buying electric vehicles. The move, which was being done to help combat high prices for gas at the pump, is turning into higher tips for some drivers as well.

Benzinga

Duck Creek Technologies Shares Crack After Q3 Results, Lowers FY22 Revenue Guidance

Duck Creek Technologies Inc (NASDAQ: DCT) reported

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Corcept Therapeutics Commences Late-Stage Ovarian Cancer Study

Corcept Therapeutics (NASDAQ: CORT) has initiated pivotal Phase 3 clinical trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer.

Benzinga

Chart Wars: Does Marathon Digital Or Riot Blockchain Have More Strength As Bitcoin, Ethereum Fall

Marathon Digital Holdings, Inc (NASDAQ: MARA) and Riot Blockchain, Inc (NASDAQ: RIOT) were plunging about 10% and 7%, respectively, on Wednesday, in exaggeration to Bitcoin (CRYPTO:

Benzinga

SMART Global Shares Plummet After Q3 Results, Guides Q4 Below Consensus

SMART Global Holdings Inc. (NASDAQ:SGH) reported third-quarter sales growth of 5.7% year-over-year to $463 million, beating the consensus of $455.17 million. Adjusted EPS of $0.87 (+24% Y/Y) beat the consensus of $0.75. The gross margin expanded by 540 bps to 24.7%, and the adjusted gross margin was up 380 bps to 25.7%.…

Benzinga

'It's Game Over': Loop Capital Analyst Warns That Bed Bath & Beyond's Days Are Limited

Bed Bath & Beyond Inc (NASDAQ: BBBY) shares hit 52-week lows on Wednesday after the company reported weak earnings results and announced a CEO transition. One analyst believes the pain is just getting started.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

After-Hours Action: Why Ammo (POWW) Shares Are Surging

AMMO Inc (NASDAQ: POWW) shares are trading higher in Wednesday's after-hours session after the company announced strong financial results that were significantly higher year-over-year.

Benzinga

McDonald's To $278? Analysts Just Raised Their Price Targets On These 5 Stocks

Investor sentiment has suffered dramatically due to the recent market downturn brought on by rising inflation, the Fed's aggressive policy and concerns about the impending economic recession.

Benzinga

Peloton Stock Dipped Today: Here's What We Know

Peloton Interactive Inc (NASDAQ: PTON) shares are trading lower Wednesday. What's going on?

Benzinga

Tigress Financial Lists Reasons Behind Bullishness On Amazon

Tigress Financial analyst Ivan Feinseth reiterated Amazon.com Inc (NASDAQ:AMZN) with a Buy and maintained a $232 price target. He saw ongoing momentum in Prime Membership, increasing traction with third-party sellers, strength in AWS, and growth and share price gains. He believed that growth in Prime membership, ongoing momentum in AWS, and increasing advertising revenue growth…

Benzinga

Here's Why Volkswagen CEO Thinks Tesla Is Weakening Itself Right Now

The battle for dominance in the electric vehicle market is heating up and Volkswagen AG (OTC: VWAGY) believes it can pass Tesla Inc (NASDAQ: TSLA) in the coming years.

Benzinga

This Analyst Believes Seagen Is Evaluating Strategic Alternatives

Raymond James initiated coverage on Seagen Inc (NASDAQ:SGEN) at Outperform with a $220 target price. Citing the recent departure of the long-time Seagen CEO, Raymond James thinks that the Board of Directors is likely evaluating strategic alternatives for the company. The relationship with Merck & Company, Inc. (NYSE:MRK) has been long-standing. With Keytruda losing its patent…

Benzinga

Analysts Still Believe Verrica's Ycanth Is Approvable Despite FDA Response Letter

Verrica Pharmaceuticals Inc (NASDAQ:VRCA) held a Type A meeting with the FDA regarding the path forward for the resubmission and potential approval of Ycanth (VP-102) for molluscum contagiosum. HC Wainwright says VP-102 was approvable, and at the time of the Complete Response Letter (CRL), Verrica had already engaged a potential alternate solution supplier. It reiterates…

1 … 314 315 316 317

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.